drugset / Trial / NCT00087386

Tanespimycin in Treating Patients With Stage III-IV Melanoma

NCT00087386

Phase 2 Terminated 50 enrolled National Cancer Institute (NCI)
NaSingle-groupOpen-labelTreatment

Summary

This phase II trial is studying how well tanespimycin works in treating patients with stage III or stage IV melanoma. Antitumor antibiotics such as tanespimycin may stop the growth of melanoma by stopping blood flow to the tumor.

Timeline

Start
2004-06
Primary completion
2007-02
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject tanespimycin Unknown Intravenous

Indications